Is Electromed (USA Stocks:ELMD) gaining more confidence from shareholders?

ELMD Stock  USD 10.43  0.40  3.99%   
In general, we focus on analyzing Electromed (USA Stocks:ELMD) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Electromed daily price indicators and compare them against related drivers. Today we will digest Electromed. We will cover the possibilities of making Electromed into a steady grower in March.
Published over a month ago
View all stories for Electromed | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Gabriel Shpitalnik

Our trade advice tool can cross-verify current analyst consensus on Electromed and to analyze the company potential to grow in the current economic cycle.
About 23.0% of the company shares are held by company insiders. The book value of Electromed was currently reported as 4.02. Electromed had not issued any dividends in recent years.
The successful prediction of Electromed stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Electromed, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Electromed based on Electromed hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Electromed's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Electromed's related companies.

Use Technical Analysis to project Electromed expected Price

Electromed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Electromed technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Electromed trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How does Electromed utilize its cash?

To perform a cash flow analysis of Electromed, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Electromed is receiving and how much cash it distributes out in a given period. The Electromed cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Electromed Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (788,900)

Breaking it down

Electromed reported the previous year's revenue of 41.66 M. Net Income was 2.31 M with profit before overhead, payroll, taxes, and interest of 31.44 M.
 2022 2023 (projected)
Interest Expense44.88 K63.41 K
Gross Profit36.16 M30.44 M

Cost of Revenue Breakdown

Electromed Cost of Revenue is increasing over the years with slightly volatile fluctuation. Cost of Revenue is expected to dwindle to about 9.9 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Electromed Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 11.75 Million
20165.29 Million
20176.53 Million
20187.45 Million
20197.27 Million
20208.45 Million
202110.22 Million
202211.75 Million
20239.92 Million

Electromed showing appearance of lower volatility

Latest Sortino Ratio is up to 0.08. Price may dip again. Electromed has relatively low volatility with skewness of 0.95 and kurtosis of 1.55. However, we advise all investors to independently investigate Electromed to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Electromed's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Electromed's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Electromed

Although some firms within the medical devices industry are still a little expensive, even after the recent corrections, Electromed may offer a potential longer-term growth to shareholders. To conclude, as of the 13th of February 2023, our actual 90 days buy-hold-sell advice on the firm is Cautious Hold. We believe Electromed is undervalued with below average probability of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Electromed. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to